CTXR files 8-K for October 2025 Corporate Presentation

Rhea-AI Filing Summary

Citius Pharmaceuticals reported that it posted an updated Corporate Presentation on its website and furnished it as Exhibit 99.1 in an Item 7.01 Regulation FD disclosure. The company noted that this information is not deemed “filed” under Section 18 of the Exchange Act and is not incorporated by reference unless specifically referenced in a future filing.

false 0001506251 0001506251 2025-10-23 2025-10-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) October 23, 2025

Citius Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Nevada

(State or other jurisdiction of incorporation)

001-38174		27-3425913
(Commission File Number)		(IRS Employer Identification No.)

11 Commerce Drive, 1st Floor, Cranford, NJ		07016
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code (908) 967-6677

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, $0.001 par value		CTXR		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On October 23, 2025, Citius Pharmaceuticals, Inc. posted an updated Corporate Presentation on its website. A copy of the Corporate Presentation is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

The following exhibit is filed herewith:

Exhibit No.		Description
99.1		Corporate Presentation of October 2025.
104		Cover Page Interactive Date File (embedded within the Inline XBRL document).

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CITIUS PHARMACEUTICALS, INC.
Date: October 23, 2025	/s/ Leonard Mazur
	Leonard Mazur
	Chairman and Chief Executive Officer

2

FAQ

What did Citius Pharmaceuticals (CTXR) announce in this 8-K?

The company posted an updated Corporate Presentation on its website and furnished it as Exhibit 99.1 under Item 7.01 (Regulation FD).

Is the Corporate Presentation deemed 'filed' for liability purposes?

No. The company states the Item 7.01 information (including Exhibit 99.1) is not deemed “filed” under Section 18 of the Exchange Act.

Where can I find the presentation referenced by CTXR?

It is attached as Exhibit 99.1 to the report and is posted on the company’s website.

What is the date of the reported event for CTXR?

October 23, 2025.

Which executive signed the report for CTXR?

Leonard Mazur, Chairman and Chief Executive Officer.

What other exhibit is included in the filing?

Exhibit 104, the Cover Page Interactive Data File embedded within the Inline XBRL document.